KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Curent Deferred Tax Liability (2009 - 2012)

Bristol Myers Squibb (BMY) reported Curent Deferred Tax Liability of -$10.0 million for Q4 2012, down 66.67% year-over-year from -$30.0 million in Q1 2012, and down 66.67% on a QoQ basis from -$6.0 million in Q4 2011.

Bristol Myers Squibb (BMY) has 4 years of Curent Deferred Tax Liability data on file, last reported at -$10.0 million in Q4 2012.

  • Quarterly Curent Deferred Tax Liability fell 66.67% year-over-year to -$10.0 million in Q4 2012, while the trailing twelve-month figure through Dec 2012 was -$10.0 million (down 66.67% YoY) and the FY2012 annual result came in at -$10.0 million, down 66.67% from the prior year.
  • Curent Deferred Tax Liability eased to -$10.0 million in Q4 2012 per BMY's latest filing, from -$6.0 million in the prior quarter.
  • Across five years, Curent Deferred Tax Liability topped out at $8.0 million in Q4 2009 and bottomed at -$10.0 million in Q4 2012.
  • The 4-year median for Curent Deferred Tax Liability is -$5.5 million (2010), against an average of -$3.2 million.
  • The widest annual swing landed in 2010, when Curent Deferred Tax Liability slumped 162.5%; it then decreased 20.0% in 2011.
  • Tracing BMY's Curent Deferred Tax Liability over 4 years: stood at $8.0 million in 2009, then tumbled by 162.5% to -$5.0 million in 2010, then fell by 20.0% to -$6.0 million in 2011, then tumbled by 66.67% to -$10.0 million in 2012.
  • Per Business Quant, the three latest BMY Curent Deferred Tax Liability figures stand at -$10.0 million (Q4 2012), -$6.0 million (Q4 2011), and -$5.0 million (Q4 2010).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Curent Deferred Tax (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2012 -10.00 Mn
Dec 31, 2012 -10.00 Mn
Dec 31, 2011 -6.00 Mn
Dec 31, 2011 -6.00 Mn
Dec 31, 2010 -5.00 Mn
Dec 31, 2010 -5.00 Mn
Dec 31, 2009 8.00 Mn
Dec 31, 2009 8.00 Mn